Kinoxis

Kinoxis Therapeutics Pty Ltd is an Australian-based, clinical-stage biotechnology company developing first-in-class therapeutics targeting ALOX15, a key regulator of neuroinflammation and neural excitability in the brain. Their lead clinical candidate, KNX100, is a short-acting small-molecule inhibitor of ALOX15, currently being evaluated in the CARES-X Phase 2 clinical trial in Australia for the treatment of acute agitation and aggression associated with dementia. The company is also advancing KNX101, a second-generation, long-acting ALOX15 inhibitor designed to address acute and chronic pain and chronic agitation through sustained modulation of neuroinflammatory signaling pathways. Kinoxis Therapeutics was founded in 2017 and is headquartered in Melbourne, Victoria, Australia.

Visit website ↗